Analysis of clinical and pathological characteristics of anti-Ro52-positive primary biliary cholangitis

Le résumé fourni par la source

By collecting and summarizing relevant clinical data from patients with primary biliary cholangitis (PBC), we compared the clinical and pathological characteristics between anti-Ro52-positive and anti-Ro52-negative PBC to further investigate the role of this antibody in PBC. A retrospective analysis was conducted on 53 patients with PBC treated at our hospital from January 2013 to January 2024. The cohort was divided into two groups: anti-Ro52-positive PBC ( n = 17) and anti-Ro52-negative PBC ( n = 36). General patient information, laboratory test results, and liver histopathology data were collected for each patient. In the anti-Ro52-positive PBC, skin icterus and scleral icterus were more common than in the anti-Ro52-negative PBC. Anti-Ro52-positive PBC patients exhibited lower albumin, red blood cell, and hemoglobin levels compared to anti-Ro52-negative PBC patients. Conversely, anti-Ro52-positive PBC patients demonstrated higher levels of globulin, immunoglobulin G, total bilirubin, direct bilirubin, and red blood cell distribution width compared to anti-Ro52-negative PBC patients. The positive rates for anti-SSA and anti-nuclear membrane antinuclear antibodies were higher in anti-Ro52-positive PBC than in anti-Ro52-negative PBC. Anti-Ro52-positive PBC patients predominantly exhibited stage S3-S4 liver fibrosis. The incidence of biochemical response after one year of ursodeoxycholic acid treatment was lower in the anti-Ro52-positive PBC than in the anti-Ro52-negative PBC. All of these differences were statistically significant ( P < 0.05). Anti-Ro52-positive PBC patients were more likely to have bilirubin elevation, skin and sclera yellow staining, and had a tendency to hypoproteinemia and anemia. Anti-Ro52-positive had adverse effects on the prognosis and the severity of the disease of PBC patients.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.